Ashford Capital Management Inc Y M Abs Therapeutics, Inc. Transaction History

Ashford Capital Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$3.0 - $15.17 $9,300 - $47,027	-3,100 Reduced 3.04%	98,870 $482,000
Q3 2022 Nov 15, 2022	SELL	$13.96 - $19.67 $31,130 - $43,864	-2,230 Reduced 2.14%	101,970 $1.47 Million
Q2 2022 Aug 15, 2022	SELL	$8.22 - $15.13 $21,125 - $38,884	-2,570 Reduced 2.41%	104,200 $1.58 Million
Q1 2022 May 16, 2022	SELL	$6.55 - $17.42 $782,135 - $2.08 Million	-119,410 Reduced 52.79%	106,770 $1.27 Million
Q4 2021 Feb 15, 2022	SELL	$15.51 - $29.31 $3.5 Million - $6.62 Million	-225,930 Reduced 49.97%	226,180 $3.67 Million
Q3 2021 Nov 15, 2021	SELL	$27.47 - $37.31 $3.61 Million - $4.9 Million	-131,398 Reduced 22.52%	452,110 $12.9 Million
Q2 2021 Aug 26, 2021	BUY	$25.45 - $37.64 $1.92 Million - $2.84 Million	75,425 Added 14.85%	583,508 $19.7 Million
Q1 2021 May 14, 2021	BUY	$29.16 - $51.96 $8.42 Million - $15 Million	288,664 Added 131.56%	508,083 $15.4 Million
Q4 2020 Feb 16, 2021	BUY	$37.86 - $54.26 $8.31 Million - $11.9 Million	219,419 New	219,419 $10.9 Million

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Ashford Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Ashford Capital Management Inc with notifications on news.